The U.S. Food and Drug Administration (FDA) updated the indication and usage section of the dapagliflozin label, effective October 31, 2025. The revised label now explicitly states that dapagliflozin tablets are indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who also have either established cardiovascular disease or multiple cardiovascular risk factors.
Background
Dapagliflozin is a medication used in the management of type 2 diabetes mellitus. This label revision specifically addresses its role in cardiovascular risk reduction. The updated indication highlights the drug's benefit in a population prone to cardiovascular complications, particularly heart failure. By reducing the risk of hospitalization for heart failure, dapagliflozin offers a significant therapeutic option for adults with type 2 diabetes mellitus who are at an elevated risk due to existing cardiovascular disease or multiple cardiovascular risk factors.
What this means
The updated indication for dapagliflozin provides important clarity for clinicians. It formally recognizes the drug's utility beyond glycemic control, extending to a crucial cardiovascular outcome: the reduction of heart failure hospitalizations. This is particularly relevant for adults living with type 2 diabetes mellitus, a population known to be at increased risk for cardiovascular events. The explicit mention of patients with established cardiovascular disease or multiple cardiovascular risk factors helps healthcare providers identify appropriate candidates for this therapy, potentially improving patient outcomes by mitigating a significant complication associated with diabetes.
Source
The information regarding this label revision was sourced from the U.S. Food and Drug Administration (FDA). The updated indication and usage for dapagliflozin were made effective on October 31, 2025, and are available on dailymed.nlm.nih.gov.